Description: Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Home Page: www.marinomed.com
Hovengasse 25
Korneuburg,
2100
Austria
Phone:
43 2262 90300
Officers
| Name | Title |
|---|---|
| Mr. Andreas Grassauer Ph.D. | Co-Founder, Chairman of Management Board & CEO |
| Ms. Eva Prieschl-Grassauer Ph.D. | Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer |
| Mr. Pascal Schmidt | CFO & Member of Management Board |
| Ms. Stephanie Kniep | Head of Investor Relations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 3.2435 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |